Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

pembrolizumab 1255 Specimen Handling 871 Carboplatin 820 Magnetic Resonance Spectroscopy 809 Cyclophosphamide 799 Cisplatin 719 Nivolumab 645 Paclitaxel 626 Radiotherapy 565 Gemcitabine 563 Biopsy 532 Bevacizumab 471 Dexamethasone 435 fludarabine 406 Docetaxel 370 venetoclax 365 Oxaliplatin 362 Fluorouracil 353 Capecitabine 350 atezolizumab 342 Rituximab 329 durvalumab 328 Doxorubicin 314 Radiosurgery 306 Pemetrexed 303 Drug Therapy 294 Standard of Care 293 Ipilimumab 288 Etoposide 279 Radiation 279

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × DLL3 protein, human × 1 year × Clear all

NCT06893783 2026-04-13

DeLLight

Asan Medical Center

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡